Dual inhibition of VEGF pathway: Phase I trial of bevacizumab and cediranib in advanced solid tumors.

3065 Background: We evaluated the safety of a combination of bevacizumab (B) and a TKI against VEGFR-cediranib (C). Methods: This was a phase I study with 3+3 design in patients (pts) with advanced...